Glecirasib KRAS G12C Inhibitor — PatSnap Eureka
Glecirasib KRAS G12C Inhibitor: Phase III in NSCLC & CRC
The KRAS G12C oncogenic mutation drives a significant proportion of non-small cell lung cancer and colorectal cancer cases. Glecirasib (JAB-21822), partnered with Johnson & Johnson, is now in Phase III development — competing directly with approved agents adagrasib and sotorasib across both indications.
The KRAS G12C Mutation: One of Oncology's Most Pursued Targets
The KRAS G12C oncogenic mutation drives a significant proportion of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) cases, representing one of the most actively pursued targets in modern oncology. This glycine-to-cysteine substitution at codon 12 locks KRAS in a constitutively active state, fuelling uncontrolled tumour proliferation through downstream RAS-MAPK and PI3K-AKT signalling.
All three leading inhibitors — glecirasib, adagrasib, and sotorasib — covalently bind the mutant cysteine residue within the KRAS switch-II pocket, trapping the protein in its inactive GDP-bound state. This shared mechanism of action defines the competitive landscape and shapes the IP strategies of Jacobio Pharmaceuticals, Mirati/BMS, and Amgen.
Understanding the molecular distinctions between these agents — selectivity profiles, resistance mechanisms, and combination strategies — is critical for R&D teams tracking this space via platforms such as PatSnap's analytics suite and PatSnap Eureka. Global patent filings around KRAS G12C have accelerated dramatically since 2019, tracked by organisations including WIPO and the EPO.
KRAS G12C Inhibitor Landscape: Key Metrics
Patent and literature signals across the three leading KRAS G12C inhibitor programs — glecirasib, adagrasib, and sotorasib — in NSCLC and CRC.
Clinical Development Stage by Inhibitor & Indication
Glecirasib is in Phase III for both NSCLC and CRC; adagrasib and sotorasib hold approved status in NSCLC, with adagrasib also approved in CRC.
Key Phase III Trial Programs by Inhibitor
Each KRAS G12C inhibitor is anchored by a named Phase III registration trial — KRYSTAL-10 (glecirasib), KRYSTAL-1 (adagrasib), and CodeBreaK 300 (sotorasib).
Glecirasib vs. Adagrasib vs. Sotorasib: Three-Way Race
Each of the three KRAS G12C inhibitors carries distinct clinical, IP, and partnership profiles across the NSCLC and CRC competitive landscape.
KRYSTAL-10: J&J-Backed Phase III in NSCLC & CRC
Glecirasib (JAB-21822) is partnered with Johnson & Johnson and is advancing through Phase III clinical development in both NSCLC and CRC indications. The KRYSTAL-10 trial represents a direct registration-enabling program. Jacobio Pharmaceuticals, the originating company, has built a focused KRAS G12C IP portfolio around the switch-II pocket binding mechanism.
Phase III · NSCLC & CRCKRYSTAL-1: First Approved in NSCLC, Now CRC-Labelled
Adagrasib (MRTX849), developed by Mirati Therapeutics and now partnered with Bristol-Myers Squibb, is an approved KRAS G12C inhibitor in NSCLC and has received regulatory approval in CRC. The KRYSTAL-1 program established the clinical proof-of-concept for this target class. Adagrasib's approval sets the efficacy and safety bar that glecirasib must surpass in Phase III.
Approved · NSCLC & CRCCodeBreaK 300: First-in-Class Approval, CRC Phase III Ongoing
Sotorasib (AMG-510) by Amgen was the first KRAS G12C inhibitor to receive regulatory approval, establishing the target's druggability in NSCLC. The CodeBreaK 300 trial is evaluating sotorasib in CRC. As the pioneer in this class, Amgen's IP estate around AMG-510 is foundational and represents a significant freedom-to-operate consideration for all subsequent entrants including glecirasib.
Approved NSCLC · Ph.III CRCSwitch-II Pocket: The Shared Binding Site Defining IP Boundaries
All three inhibitors — glecirasib, adagrasib, and sotorasib — covalently bind the mutant cysteine residue within the KRAS switch-II pocket, trapping the protein in its inactive GDP-bound state. This shared mechanism creates overlapping IP territories and drives differentiation strategies focused on selectivity, CNS penetration, resistance mechanisms, and combination regimens with SOS1 inhibitors and other agents.
Switch-II Pocket · Covalent BindingGlecirasib vs. Adagrasib vs. Sotorasib: Key Attributes
A structured comparison of the three leading KRAS G12C inhibitors across clinical, molecular, and commercial dimensions.
| Attribute | Glecirasib (JAB-21822) | Adagrasib (MRTX849) | Sotorasib (AMG-510) |
|---|---|---|---|
| Originator | Jacobio Pharmaceuticals | Mirati Therapeutics | Amgen |
| Commercial Partner | Johnson & Johnson KRYSTAL-10 | Bristol-Myers Squibb KRYSTAL-1 | Amgen (self-partnered) CodeBreaK 300 |
| NSCLC Status | Phase III | Approved | Approved |
| CRC Status | Phase III | Approved | Phase III |
| Binding Mechanism | Covalent · Switch-II pocket | Covalent · Switch-II pocket | Covalent · Switch-II pocket |
| Target Residue | Mutant Cys12 | Mutant Cys12 | Mutant Cys12 |
Need deeper competitive benchmarking?
PatSnap Eureka surfaces patent filings, clinical signals, and assignee strategies across the full KRAS G12C inhibitor space.
Why the KRAS G12C Race Matters for IP & R&D Teams
Four critical strategic dimensions shaping the glecirasib, adagrasib, and sotorasib competitive landscape in 2025.
KRAS G12C: One of Oncology's Most Actively Pursued Targets
The KRAS G12C oncogenic mutation drives a significant proportion of NSCLC and CRC cases, making it one of the most actively pursued targets in modern oncology. Patent filings around this target have accelerated dramatically since sotorasib's first-in-class approval, with Jacobio, Mirati/BMS, and Amgen all building dense IP estates tracked by the EPO and WIPO.
J&J Partnership Signals Glecirasib's Commercial Ambition
Glecirasib's partnership with Johnson & Johnson signals significant commercial intent for the Phase III program. For R&D teams and IP strategists, this partnership changes the competitive calculus — J&J's resources and regulatory expertise make glecirasib a credible challenger to the approved adagrasib and sotorasib franchises. PatSnap customers track these partnership signals in real time.
Key Organisations Driving KRAS G12C Innovation
The KRAS G12C inhibitor IP landscape is shaped by four primary assignees: Jacobio Pharmaceuticals (glecirasib/JAB-21822), Mirati Therapeutics / Bristol-Myers Squibb (adagrasib/MRTX849), and Amgen (sotorasib/AMG-510). Each has built a layered patent portfolio covering the core switch-II pocket binding mechanism, formulation strategies, combination therapies, and biomarker selection methods.
For R&D teams and IP counsel, tracking these assignee-specific filing patterns is essential for freedom-to-operate assessments and white-space identification. PatSnap's analytics platform enables real-time assignee monitoring across all three programs. The NIH's ClinicalTrials.gov database provides complementary clinical trial registration data for KRYSTAL-10, KRYSTAL-1, and CodeBreaK 300.
Beyond the three primary inhibitors, the KRAS G12C space is attracting a growing cohort of next-generation entrants focused on overcoming acquired resistance — a key strategic opportunity identified via PatSnap's innovation intelligence platform. Developers can also access raw data via PatSnap's open API for custom assignee tracking workflows.
Glecirasib KRAS G12C Inhibitor — key questions answered
Glecirasib (JAB-21822) is a KRAS G12C inhibitor developed by Jacobio Pharmaceuticals and partnered with Johnson & Johnson. It is advancing through Phase III clinical development in both non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), placing it in direct competition with approved agents adagrasib and sotorasib.
KRYSTAL-10 is a Phase III clinical trial evaluating glecirasib (JAB-21822) in partnership with Johnson & Johnson. It is one of the key registration trials for glecirasib in the KRAS G12C inhibitor competitive landscape alongside adagrasib's KRYSTAL-1 program and sotorasib's CodeBreaK 300 trial.
Glecirasib (JAB-21822), adagrasib (Mirati/BMS), and sotorasib (Amgen) are all KRAS G12C inhibitors targeting the switch-II pocket of the KRAS protein. Adagrasib and sotorasib are already approved, while glecirasib is in Phase III development. All three compete in both NSCLC and CRC indications.
The KRAS G12C oncogenic mutation drives a significant proportion of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) cases, representing one of the most actively pursued targets in modern oncology. The mutation results in a glycine-to-cysteine substitution at codon 12 of the KRAS protein.
The key companies in the KRAS G12C inhibitor competitive landscape include Jacobio Pharmaceuticals (glecirasib/JAB-21822, partnered with Johnson & Johnson), Mirati Therapeutics/Bristol-Myers Squibb (adagrasib/MRTX849), and Amgen (sotorasib/AMG-510). Each company is pursuing development across NSCLC and CRC indications.
KRAS G12C inhibitors including glecirasib, adagrasib, and sotorasib are primarily being developed for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The KRAS G12C oncogenic mutation drives a significant proportion of cases in both indications, making them the primary targets for clinical development.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About KRAS G12CTrack Glecirasib, Adagrasib & Sotorasib in Real Time
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D intelligence on KRAS G12C and the broader oncology pipeline.
References
- WIPO — World Intellectual Property Organization: Global Patent Filing Data
- European Patent Office (EPO) — KRAS G12C Patent Landscape
- NIH ClinicalTrials.gov — KRYSTAL-10, KRYSTAL-1, CodeBreaK 300 Trial Registrations
- PatSnap Life Sciences Intelligence Platform
- PatSnap Analytics — Competitive IP Intelligence
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Clinical development status information reflects publicly available patent and literature records as of July 2025.
PatSnap Eureka searches patents and research to answer instantly.